Finally, some data.
Here is where Azer-cel + chemotherapy compares to some of the other Allogeneic CAR-T therapies in combination with chemotherapy.
In comparison to peer allogeneic CAR T therapies, Azer-cel appears to be underperrforming as well as lagging behind in clinical development. With so many competitors, the risk of clinical and moreso commercial success is very high.
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00554-0/fulltext
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7025
https://www.sciencedirect.com/science/article/pii/S0006497121022990
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32334-5/abstract
https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2517
https://www.nature.com/articles/s41591-023-02785-8
- Forums
- ASX - By Stock
- Ann: Three Complete Responses in Azer-Cel Phase 1b Trial
Finally, some data.Here is where Azer-cel + chemotherapy...
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
7.6¢ |
Change
0.014(22.6%) |
Mkt cap ! $587.9M |
Open | High | Low | Value | Volume |
7.3¢ | 8.1¢ | 7.3¢ | $9.571M | 123.3M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 2182036 | 7.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.7¢ | 934673 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 1779994 | 0.078 |
13 | 2144395 | 0.077 |
19 | 5962573 | 0.076 |
11 | 2259333 | 0.075 |
9 | 4234571 | 0.074 |
Price($) | Vol. | No. |
---|---|---|
0.079 | 117517 | 6 |
0.080 | 1488651 | 22 |
0.081 | 1763019 | 12 |
0.082 | 2436196 | 14 |
0.083 | 1151634 | 10 |
Last trade - 11.55am 02/09/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online